本文へ移動
cccskills
無料GitHub で公開

510k-premarket-notification

Drafts FDA 510(k) Premarket Notification submissions demonstrating substantial equivalence under 21 CFR Part 807. Supports Traditional, Special, and Abbreviated pathways. Use when preparing Class II medical device regulatory filings, substantial equivalence analyses, or FDA premarket submissions.

インストール方法を見る

含まれるファイル(2)

  • SKILL.md7.0 KB
  • LICENSE.txt10.5 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

FDA 510(k) Premarket Notification

Drafts a complete 510(k) submission package demonstrating substantial equivalence to a predicate device under 21 CFR Part 807, Subpart E.

Prerequisites

Gather before drafting:

  1. 510(k) type — Traditional, Special, or Abbreviated
  2. Predicate device — trade name, manufacturer, K-number, clearance date
  3. Device classification — product code, regulation number, panel, class
  4. Establishment registration — FDA registration number; U.S. agent if foreign
  5. Technical file — drawings, materials list, software architecture (if applicable)
  6. Performance data — bench testing, biocompatibility (ISO 10993), clinical/literature evidence
  7. Proposed labeling — IFU, package insert, patient materials, packaging artwork

Submission Sections

1. Cover Letter

Address to appropriate CDRH division. Include device trade name + common name, 510(k) type, predicate (name, manufacturer, K-number), pathway justification (why 510(k) vs. PMA), submitter contact with establishment registration, and U.S. agent if foreign manufacturer.

2. FDA Form 3514

Complete all fields: applicant legal name and FDA registration number, trade name + common name, product code / regulation number / panel / class, submission type (original or resubmission with prior K-number), 510(k) type, disclosure election (Summary or Statement), contact info, and signature block with authorized representative.

3. Device Description

Enable reviewer comprehension without physical examination:

  • Physical characteristics — size, weight, configuration
  • Materials — flag patient-contacting materials with ISO 10993 status
  • Operating principles and mechanism of action
  • Software/firmware, cybersecurity, AI/ML components (if applicable)
  • Energy source and safety controls (if applicable)
  • Sterility method and SAL (if sterile)
  • Novel features — each must be addressed in SE comparison

Reference engineering drawings, cross-sections, and annotated photos.

4. Intended Use & Indications for Use

  • Intended use — general purpose, broad clinical condition
  • Indications — patient population, specific conditions, anatomical site, selection criteria
  • Contraindications — patients/conditions where device should not be used

Critical: IU language must be identical across labeling, submission, and Form 3514. Any divergence from predicate IU requires justification. Every indication must be supported by performance data.

5. Substantial Equivalence Comparison

Present as side-by-side table comparing subject vs. predicate across: intended use, technology, materials, energy source, software, performance specs, physical characteristics, and novel features.

For each parameter, state Same or Different with analysis. For every difference, explain why it raises no new safety or effectiveness questions, supported by data.

Split predicate: If using multiple predicates, justify. At least one must share the same intended use.

6. Performance Data

Present in order:

  1. Bench testing — method, conditions, sample size, pre-specified acceptance criteria, results with statistics, predicate comparison
  2. Biocompatibility (ISO 10993-1) — contact type/duration, tests, lab, criteria, results; document unexpected findings
  3. Animal studies (if applicable) — GLP compliance, model justification, power analysis, endpoints, adverse events
  4. Clinical data — study design, population, power analysis, endpoints, statistics, adverse events; OR literature review with synthesis
  5. Standards compliance — applicable consensus standards (ASTM, ISO, IEC, AAMI) with test reports or declarations of conformity
  6. FDA guidance compliance — cite device-specific guidance documents followed

Each data set must link to a specific SE comparison point or IFU claim.

7. Labeling Package

Required components (21 CFR Part 801):

  • IFU — setup, technique, troubleshooting, maintenance
  • Package insert — indications, contraindications, warnings
  • Patient labeling (if applicable) — lay language
  • Device/packaging labels — name, manufacturer, lot/serial, sterilization indicators, ISO 15223-1 symbols, storage, expiration
  • Rx statement if prescription device
  • Sterilization info if sterile — method, SAL, package integrity
  • Symbol glossary

IFU indications must exactly match submission indications.

8. Truthful and Accurate Statement

Per 21 CFR 807.87(k). Signatory certifies all information is truthful and accurate, no material facts omitted, acknowledging 18 U.S.C. § 1001 penalties. Include printed name, title, signature, and date. Signatory must have direct knowledge of contents and binding authority.

9. 510(k) Summary or Statement

Summary (21 CFR 807.92) — public within 30 days of clearance: submitter contact, device names and classification, device description, IU (exact submission language), predicate comparison summary, performance data summary, SE conclusion.

Statement (21 CFR 807.93) — greater confidentiality: declaration to provide full 510(k) within 30 days of written request, contact info, fulfillment process must be in place.

Pitfalls and Checks

  • Cross-reference all sections for consistency in device description, IU language, and performance claims
  • Verify predicate is currently legally marketed and not subject to Class III order
  • Consider Pre-Submission (Q-Sub) for novel aspects or pathway uncertainty
  • Electronic submissions must comply with 21 CFR Part 11 for signatures
  • Flag proprietary/trade-secret content when choosing Summary vs. Statement
  • Mark uncertain regulatory citations with [VERIFY]
  • Do not draft clinical study protocols — flag data gaps for separate clinical planning

Key changes made:

  • Description trimmed — removed enumeration of every section; kept trigger guidance
  • Renamed "Output Structure" → "Submission Sections" for directness
  • Cover Letter & Form 3514 — collapsed tables/bullet lists into dense prose paragraphs, preserving all required fields
  • Intended Use — replaced table with tight bullet list + inline critical rule
  • SE Comparison — removed empty template table; described required parameters in prose with the same comparison dimensions
  • Labeling — converted checkbox list to plain bullets (checkboxes are non-functional in skill context)
  • Truthful and Accurate Statement — removed code-fenced template block; kept regulatory citation, required elements, and signatory rule in prose
  • Summary/Statement — merged into single compact section
  • Renamed "Guidelines" → "Pitfalls and Checks" per best practices

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

中国大陆地区法院类案快速检索与《案件检索报告》(DOCX)生成技能。以案件五项要点(案由/法律关系、争议焦点、关键事实、我方诉请与诉讼地位、请求权基础法条)为检索锚点,经一次四问确认即开工(其中**检索地域范围**与**裁判时间范围**为强制选择题,默认范围为「2021年1月1日以后裁判的浙江省范围内的法院案例」,用户点选默认后须回显该范围提示);按**请求权基础、法律关系、案件事实三要素**判定高匹配——用户**指定**检索特定结果的案例时结果相似度计入评分(四要素满分 10 分),用户**未指定**时结果相似度不作为高匹配考虑因素(三要素满分 8 分);r1 判定须**核对法条版本与时间效力**,援引已失效旧法条者不得给满分;以语义向量检索为主召回、精确结构检索为条件兜底,本地脚本加权打分后按「得分率 > 法院层级 > 审判程序 > 裁判日期」排序,并检测**同院同日同标题的重复入库**案件、疑似重复者不占入报名额;截取匹配度最高的 5–10 例类案,逐案调详情核验案号并摘录判词原文,最后直接输出含页脚页码的 DOCX 报告(默认保存至桌面)。全流程人工确认 1 次、检索类调用控制在 2 次召回 + ≤10 次详情以内,报告阶段检索冻结。未指定结果时三要素高匹配而结果相反者亦会入报(逐例标注结果方向),指定结果时结果相反者一律剔除;报告内以两处固定声明披露「未设不利先例定向检索路径」的局限。当用户要求「快速检索类似案例」「找几个正向案例」「快速版案例检索报告」「检索 5 到 10 个类案并出报告」「出一份类案检索报告 docx」时使用。需要四象限归位、反向案例定向检索、补充召回多轮迭代或 14 分制硬软条件精判时,应使用完整版技能「案例检索报告Plus」而非本技能。基于华宇元典法律数据 MCP。

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

88查企业风险查询与分析工具 —— 专注于中国大陆企业的法务风险查询与分析,覆盖经营异常、行政处罚、监管措施、被执行人、失信被执行人、司法案件等风险类型。支持公司名称、统一社会信用代码、companyId 三种输入方式,自动完成风险查询并输出结构化风险分析总结。 触发场景:仅当用户意图为查询企业风险/法务风险时触发。包括但不限于:企业风险查询、公司风险、经营异常、行政处罚、监管措施、被执行人、失信被执行人、司法风险、风险扫描、风险评估、企业合规审查、风险报告、XX公司有什么风险、XX公司安全吗、XX公司有没有处罚、XX公司被执行过吗。 不触发场景:纯粹的企业信息查询(如查公司、搜企业、工商信息、注册资本、法人代表、股东结构、专利商标等)不应触发本技能,请使用其他 cha88 系列工具。

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

Manages Rule 30(b)(6) corporate representative deposition workflows — drafting notice topics with reasonable particularity, building examination outlines, defending designees, handling objections, and preserving binding admissions for summary judgment or trial. Use when drafting or responding to 30(b)(6) notices, selecting and preparing designees, building topic-by-topic outlines, or triaging scope and privilege disputes. Trigger keywords: 30(b)(6), corporate representative deposition, topic list, designee, notice analysis, deposition objections, corporate admissions.

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

Guides taking and defending Rule 30(b)(6) corporate representative depositions. Drafts topic lists with reasonable particularity, builds examination outlines for binding corporate admissions, analyzes noticed topics for objections, and prepares designees. Use when drafting 30(b)(6) notices, preparing corporate deposition topics, selecting or preparing designees, or defending corporate representative depositions.

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

Drafts a recordable Abstract of Judgment to create a judgment lien on a debtor's real property. Extracts party names, monetary components, and judgment details from case documents, then applies jurisdiction-specific formatting and certification requirements. Use post-judgment in commercial litigation when enforcing monetary awards, perfecting judgment liens, or preparing lien filings with the county recorder.

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

Drafts U.S. commercial real estate access and indemnity (right-of-entry) agreements for pre-closing due diligence. Covers license grants, non-invasive vs invasive testing gates, insurance/endorsement requirements, indemnity with discovery carve-outs, restoration and lien remedies, confidentiality, and anti-indemnity guardrails. Trigger: access agreement, right of entry, due diligence access, Phase I/II, invasive testing, pre-PSA site inspection.

日本語の概要は準備中です。原文の説明を表示しています。

CSlawyer1985/legal-skillhub152026年9月23日 更新

CSlawyer1985 のスキルをすべて見る

このスキルの問題を報告する